Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels

Deepa R. J. Arachchillage; Maria Efthymiou; Andrew S. Lawrie; Samuel J. Machin; Ian J. Mackie; Hannah Cohen

doi:10.1160/TH14-01-0050

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2014; 112(02): 421-423
DOI: 10.1160/TH14-01-0050

Letters to the Editor

Schattauer GmbH

Comparative sensitivity of commonly used thromboplastins to ex vivo therapeutic rivaroxaban levels

Deepa R. J. Arachchillage

¹Haemostasis Research Unit, Department of Haematology, University College London, London, UK

,

Maria Efthymiou

¹Haemostasis Research Unit, Department of Haematology, University College London, London, UK

,

Andrew S. Lawrie

¹Haemostasis Research Unit, Department of Haematology, University College London, London, UK

,

Samuel J. Machin

¹Haemostasis Research Unit, Department of Haematology, University College London, London, UK

,

Ian J. Mackie

¹Haemostasis Research Unit, Department of Haematology, University College London, London, UK

,

Hannah Cohen

¹Haemostasis Research Unit, Department of Haematology, University College London, London, UK

²Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK

References
1 Baglin T, Hillarp A, Tripodi A. et al. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013; 11: 756-760.
2 Baglin T, Keeling D, Kitchen S. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology. Br J Haematol 2012; 159: 427-429.
3 Hillarp A, Baghaei F, Fagerberg B. et al. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 09: 133-139.
4 Samama MM, Martinoli JL, LeFlem L. et al. Assessment of laboratory assays to measure riva-roxaban--an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-825.
5 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
6 Rohde G. Determination of rivaroxaban--a novel, oral, direct Factor Xa inhibitor--in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 43-50.
7 Mueck W, Borris LC, Dahl OE. et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008; 100: 453-461.
8 Mueck W, Lensing AW, Agnelli G. et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet 2011; 50: 675-686.
9 Douxfils J, Tamigniau A, Chatelain B. et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 2013; 110: 723-731.
10 Patel JP, Roberts LN, Chitongo PB. et al. More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban - early experience from King’s College Hospital. Br J Haematol 2013; 162: 717-718.
11 van Veen JJ, Smith J, Kitchen S. et al. Normal prothrombin time in the presence of therapeutic levels of rivaroxaban. Br J Haematol 2013; 160: 859-861.